Gland Pharma (NSE:GLAND) Other Long-Term Liabilities : ₹3,978 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Other Long-Term Liabilities?

Gland Pharma's other long-term liabilities for the quarter that ended in Mar. 2024 was ₹3,978 Mil.

Gland Pharma's quarterly other long-term liabilities declined from Sep. 2023 (₹3,025 Mil) to Dec. 2023 (₹0 Mil) but then increased from Dec. 2023 (₹0 Mil) to Mar. 2024 (₹3,978 Mil).

Gland Pharma's annual other long-term liabilities declined from Mar. 2022 (₹895 Mil) to Mar. 2023 (₹859 Mil) but then increased from Mar. 2023 (₹859 Mil) to Mar. 2024 (₹3,978 Mil).

Gland Pharma Other Long-Term Liabilities Historical Data

The historical data trend for Gland Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Other Long-Term Liabilities Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Other Long-Term Liabilities

Get a 7-Day Free Trial

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Gland Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Gland Pharma Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines